Yunnan Baiyao Group Co.,Ltd

000538

CNE0000008X7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
51.15 ^CNY	-0.06%		-0.80%	+4.07%

12/06	Yunnan Baiyao Group Co.,Ltd Announces Board Appointments	CI
06/06	Yuyue Medical Owners Prohibited from Leaving China for Alleged Links to Baiyao Corruption Case	MT

Yunnan Baiyao Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 10 May 2024

April 30, 2024

Yunnan Baiyao Group Co.,Ltd announced final dividend of CNY 20.77 per 10 shares (tax included) on A shares for the year 2023. Record date: 09 May 2024, Ex-date: 10 May 2024 and Payment date: 10 May 2024.

Latest news about Yunnan Baiyao Group Co.,Ltd

Yunnan Baiyao Group Co.,Ltd Announces Board Appointments	13/06	CI
Yuyue Medical Owners Prohibited from Leaving China for Alleged Links to Baiyao Corruption Case	06/06	MT
Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug	13/05	MT
Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch	13/05	MT
Yunnan Baiyao Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 10 May 2024	30/04	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2023	24/04	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2023	02/04	CI
Yunnan Baiyao Group's Profit Rises 30% as Operating Income Increases	01/04	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal	22/12	MT
Yunnan Baiyao’s Profit Jumps 61% in Q3 as Revenue Rises 5%	31/23/31	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
YNBY International Plans Year-End Date Change	16/23/16	MT
Yunnan Baiyao’s Profit Jumps 88.5% in H1 as Revenue Rises 13%	30/23/30	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2022, Payable on 19 May 2023	11/23/11	CI
Chinese Shares Rebound; Yunnan Baiyao Jumps 7.5% on Robust Q1 Earnings	27/23/27	MT
Yunnan Baiyao’s Q1 Profit Jumps 66% as Revenue Rises 11.5%; Shares Climb 7%	27/23/27	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Yunnan Baiyao Group Co.,Ltd's Equity Buyback announced on May 9, 2022, has expired.	07/23/07	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2022	01/23/01	CI
Yunnan Baiyao Chairman Steps Down; Shares Fall 4%	07/23/07	MT
Yunnan Baiyao Group Co.,Ltd agreed to acquire Product Registration and Promotion, Global Supply and Professional Supporting Services of Ban Loong from Ban Loong Holdings Limited (SEHK:30).	23/22/23	CI
Yunnan Baiyao Group Co.,Ltd Announces Directorate Appointments	09/22/09	CI

Chart Yunnan Baiyao Group Co.,Ltd

Duration

Period

More charts

Company Profile

Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory. China accounts for 98.9% of net sales.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yunnan Baiyao Group Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

51.15 CNY

Average target price

65.01 CNY

Spread / Average Target

+27.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YUNNAN BAIYAO GROUP CO.,LTD	+4.07%	12.56B
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals